Treatment
- Mirvetuximab + bevacizumab versus bevacizumab alone (randomization 2:1).
- Mirvetuximab is given IV every 3 weeks.
Treatment duration
The treatment is given as maintenance therapy and up to 16 cycles can be given or until disease progression, unacceptable toxicity or withdrawal of consent.
Eligibility
Main inclusion criteria:
- Confirmed high or medium folate receptor alpha (FRa) expression by Ventana folate receptor 1 (FOLR1) Assay
- Participants must have a confirmed diagnosis of FIGO Stage III or IV high-grade serous ovarian, primary peritoneal, or fallopian tube cancer.
- Tumor must be confirmed HRD test negative (HRP), determined by a local homologous recombination deficient (HRD) test
Main exclusion criteria:
- Participants with progressive disease (PD) while on triplet therapy or after the first day of their last triplet therapy cycle and before randomization
Disclaimer: This is an overview of the main in- and exclusion criteria which can also be found on clinicaltrials.gov (NCT07059845). Criteria might change during the course of the study due to amendments. Inclusion in the trial remains the responsibility of the principal investigator of the trial and will depend on patient eligibility and slot availability.
Contact
In case you feel your patient might be eligible for this trial or in case you want to have more information about this trial, please feel free to contact us via: lgog@uzleuven.be